Daily Stock Opinions and Ratings

Wealthica The ultimate 360° Tracker Your financial life in one place, automatically

Opinions

The Panic-Proof Portfolio (Stockchase Research)Merck & CompanyMRKTOP PICKJun 11, 2026

Stockchase Research Editor: Michael O'Reilly

We reiterate MRK as a TOP PICK. Sales of its top cancer treatment drug, which accounts for the marjority of its revenues, is expected to more than triple its current $8 billion sales by 2028 and it has a long pipeline of new drugs, with plans to release over 20 by 2030. It trades at 23x earnings and supports a ROE of 27%. Cash reserves are growing, while shares are bought back, albeit with an increase in debt. We continue to recommend a stop at $110, looking to achieve $143 -- upside potential of 18%. Yield 2.7%

(Analysts’ price target is $131.56)

The Panic-Proof Portfolio (Stockchase Research)

Unknown

Unlock Rating

$120.76

Stock price when the opinion was issued

$119.05

As of Jun 12, 2026. Market Open.

biotechnologypharmaceutical

It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

Get Signals Create your Watchlist

You might be interested:

HOLD

Many drugs in the pipeline, and this compensates for older drugs going off patent. For example, it's blockbuster Keytruda is going off. You want companies that deliver double-digit revenue growth on offerings.

DON'T BUY

Today's downward move isn't all that outsized. There's been more clarity on US drug pricing. Seeing a bit of market exhaustion, as US pharma is trading at huge premiums relative to their own history.

Rerating from pricing clarity has already been baked in. R&D pipeline in the sector is a mixed bag, doesn't trust it.

BUY

He bought it for their strong drug pipeline and is happy to stay here.

HOLD

One of her holdings in the space. This higher-quality name has both growth and less execution risk.

WEAK BUY

Erratic and bumpy name. Concerns about Keytruda falling off. Pipeline (looking pretty good), execution, and valuation story. Trades at 12x PE. Just beat Q4, revenue beat. All things considered, you can own this.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 02/25, Up 42.2%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $100) to $110 at this time.

TOP PICK

Pharmas are coming back. Political policy is improving. Keytruda makes up a lot of revenues but faces a patent cliff in 2028. But MRK has invested a lot in new drugs and been buying companies strategically.

(Analysts’ price target is $123.89)

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 02/25, Up 36%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRK is progressing well. To remain disciplined, we recommend trailing up the stop (from $87) to $100 at this time.

BUY

Pays a really nice dividend. Really nice drug pipeline. Inexpensive. Reasonably wide moat.

BUY

A good drug pipeline with many promising drugs in phase 2 trials, though they have to overcome the patent cliff of Keytruda.

PAST TOP PICK

(A Top Pick Jan 09/25, Up 11%)

They have a good pipeline that will help offset the loss of their major Keytruda drug when it goes off-patent. MRK is good at buying and tucking in companies. Their 2025 chart wasn't that great until the end of the year when the sector caught a bid.

BUY

Is bullish healthcare for 2026 because of its growing customer base (baby boomers) who will need health services. He's been adding to Merck, post-Keytruda.

Premium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

(A Top Pick Sep 02/25, Up 19.3%)Stockchase Research Editor: Michael O'Reilly

Our PAST TOP PICK with MRK has triggered its stop at $173. To remain disciplined, we recommend covering half the position at this time and trailing up the stop (from $79) to $87.

BUY

He made a mistake in selling this. It's now back to $94 and wants to hit $102.97, a 52-week high.

Most Recent Experts

Jim Cramer - Mad Money

CNBC

Richard Orrell

RN Croft Financial Group

Stockchase Insights

5i Research